ONCT - Oncternal Therapeutics GAAP EPS of -$0.15 beats by $0.02 revenue of $0.11M misses by $0.06M
2023-08-10 16:02:52 ET
- Oncternal Therapeutics press release ( NASDAQ: ONCT ): Q2 GAAP EPS of -$0.15 beats by $0.02 .
- Revenue of $0.11M (-42.1% Y/Y) misses by $0.06M .
- Cash runway extended into 2025, with $45.5 million in cash, cash equivalents and short-term investments and no debt as of June 30, 2023.
For further details see:
Oncternal Therapeutics GAAP EPS of -$0.15 beats by $0.02, revenue of $0.11M misses by $0.06M